Last updated: 2026-09-16 10:31:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Aligos Therapeutics, Inc. (ALGS) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $5,04, with a market capitalisation of $31,47M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3,98 to $13,69. This page covers its latest market performance, valuation, price trends and company information.
$31,47M | |
$5,04 | |
$937,75 | |
$3,76 | |
$4,99 | |
-- | |
165,21K | |
-- | |
$13,69 | |
$3,98 | |
-- | |
-- |
Aligos Therapeutics, Inc. (ALGS) is trading at $5,04 in pre-market trading as of 2026-09-16 08:01:00, up 1,02% ($0,05) from the previous close of $4,99
Pre-market trading shows how investors are pricing ALGS before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Aligos Therapeutics, Inc. (ALGS) moved from $6,21 to $5,04, representing a decline of 18,82% ($1,17).
The stock traded between $4,82 and $6,34 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 37,59 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 10,9%
ALGS is currently trading at $5,04, placing it 10,9% of the way from its 52-week low of $3,98 to its 52-week high of $13,69. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 82 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Aligos Therapeutics, Inc. (ALGS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.